ARA-290 vs SS-31 | Research Comparison | QSC Peptides
ARA-290 vs SS-31 (Elamipretide): Research Comparison
Mechanism, research applications, and key differences
Quick Comparison
Factor
ARA-290
SS-31 (Elamipretide)
Primary Target
Innate Repair Receptor (IRR)
See SS-31 (Elamipretide) hub
Origin
EPO helix B surface peptide
Distinct origin
Key Research
Phase 2: small fibre neuropathy, metabolic repair
See SS-31 (Elamipretide) hub
Detailed Comparison
Both are cytoprotective peptides but SS-31 targets mitochondrial cardiolipin for energy production, while ARA-290 targets IRR for neuroprotection and insulin sensitivity. Complementary rather than competing mechanisms.
Which to Choose for Your Research?
The choice depends on your primary research target. ARA-290 is the right tool when the research question involves IRR-mediated cytoprotection — neuropathy models, sarcoidosis inflammation, or metabolic beta cell protection. SS-31 (Elamipretide) suits different primary targets. For comprehensive cytoprotection research, some protocols combine both compounds targeting complementary pathways.
